Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

AI-Boosted CAR/TCR Development Services

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides an AI boosted CAR/TCR Development Service to address key challenges in engineered T-cell therapy development, including poor T-cell persistence, off-target toxicities, and the labor-intensive screening of receptor candidates. This service enables the rapid identification of high-affinity leads and optimization of receptor stability through advanced deep learning architectures and high-throughput multi-omics data integration. By combining structural prediction technologies with curated signaling motif libraries, Creative Biolabs streamlines the transition from in silico receptor design to clinically relevant therapeutic candidates.

Introduction

The success of CAR/TCR therapies is limited by receptor persistence, tumor heterogeneity, and safety concerns. Current literature highlights that AI and Machine Learning can optimize every stage of development, from target antigen selection to clinical response prediction. By processing high-dimensional multi-omics datasets, AI identifies patterns that human observation may overlook, such as specific NK-cell-like phenotypes in CD8 T cells that correlate with positive clinical outcomes. In conclusion, AI-boosted platforms are essential for ushering in an era of safe, effective, and personalized immunotherapy.

Multi-layer neural network for neoantigen prediction: feature extraction and prediction workflow. (OA Literature) Fig.1 Multilayer neural network for neoantigen prediction: feature extraction and prediction workflow.¹

Our Service

Creative Biolabs provides a digital-to-biological bridge, transforming high-dimensional data into validated therapeutic candidates. By utilizing predictive modeling, we significantly reduce the "trial and error" phase of receptor engineering, allowing your team to focus on the most promising leads for hematologic or solid tumor targets. Developing effective CAR-T or TCR-T therapies requires efficient identification of receptors with high specificity, strong antitumor activity, and minimal off-target effects. We provide an integrated AI-assisted development framework that accelerates receptor discovery, optimization, and validation.

Our integrated platform combines computational screening for accelerated CAR/TCR candidate discovery, data-driven optimization for enhanced binding and function, efficient computational prioritization to reduce experimental workload, and standardized cellular assays for rigorous validation of expression, cytotoxicity, and antitumor activity.

Discover how your program can move faster and smarter. Request a consultation today.

What We Can Offer

Creative Biolabs provides a comprehensive suite of technologies that support AI-assisted CAR and TCR development.

Platform of AI Boosted CAR/ TCR Development Service. (Creative Biolabs Original)

Our Workflow

Required Starting Materials: To initiate the service, clients typically provide target antigen sequences, desired effector cell profiles, or existing scFv/TCR sequences for optimization.

Workflow of AI Boosted CAR/ TCR Development Service. (Creative Biolabs Original)

Specialty Services

AI-Driven Target & Binder Discovery Service for CAR/TCR Development

We provide AI-driven target and binder discovery services to support CAR/TCR development. By integrating multi-omics analysis, structural modeling, and machine learning–based screening, we rapidly identify tumor-associated antigens and high-affinity binders, enabling precise receptor design and accelerating early-stage immunotherapy development.

Learn More →

AI-Enhanced Construct Engineering & Design for CAR/TCR Development

Creative Biolabs applies AI-assisted modeling and modular engineering to optimize CAR/TCR construct architecture. By integrating structural prediction, signaling domain libraries, and in silico performance screening, we design receptors with improved stability, signaling strength, and functional efficiency for next-generation cell therapies.

Learn More →

AI-Powered Safety & Specificity Profiling for CAR/TCR Development

Creative Biolabs utilizes AI-driven safety and specificity profiling to predict cross-reactivity, off-target risks, and antigen similarity across the human proteome. Our platform enables early risk mitigation, improving therapeutic precision and supporting the development of safer CAR/TCR candidates.

Learn More →

AI-Boosted Manufacturing & CMC Optimization for CAR/TCR Development

Creative Biolabs integrates AI tools into CAR/TCR manufacturing and CMC workflows to optimize viral vector production, cell expansion parameters, and quality control metrics. This data-driven approach improves process robustness, scalability, and regulatory readiness for advanced cell therapy programs.

Learn More →

AI-Integrated Preclinical & Translational for CAR/TCR Development

Creative Biolabs leverages AI-powered analytics to connect preclinical findings with translational insights. By integrating biomarker discovery, patient response prediction, and multi-omics datasets, our platform supports informed decision-making and accelerates the path toward clinically relevant CAR/TCR therapies.

Learn More →

Benefits

Customized Receptor Engineering: Bespoke CAR/TCR design services tailored to specific patient populations or niche tumor types.
AI-Driven Neoantigen Identification: High-accuracy prediction of immunogenic neoantigens using CNN and LSTM architectures to bypass central tolerance.
Advanced Structural Refinement: Optimization of scFv stability and TCR-pMHC binding affinity using protein language models and structural templates.
Predictive Safety Profiling: Early-stage in silico screening for ICANS and CRS risk factors to enhance clinical safety.

FAQs

Q: How does your AI platform improve the safety of CAR-T constructs?

A: Our system predicts treatment-related toxicities, such as CRS, by analyzing serum cytokine levels and structural binders in silico, achieving over 85% sensitivity in early risk detection.

Q: What makes your neoantigen prediction different from standard pipelines?

A: We utilize integrated scoring systems, which consider MHC binding, proteasome cleavage, and tumor abundance, resulting in a significantly higher recall rate than traditional tools.

Q: Is the Black Box nature of AI a concern for regulatory filings?

A: We prioritize explainable AI models, providing the reasoning behind our predictions to ensure they are safe, effective, and transparent for healthcare integration.

Q: Does this service support TCR-T development as well as CAR-T?

A: Absolutely. Our platform specializes in both TCR-pMHC binding predictions and synthetic CAR costimulatory domain optimization.

Partner with Us

Creative Biolabs offers an industry-leading AI Boosted CAR/TCR Development Service designed to de-risk your pipeline and maximize therapeutic efficacy through advanced computational modeling and biological expertise. From target identification to manufacturing optimization, we are your partner in digital precision medicine. Please contact our specialist team directly via email or visit our contact portal for detailed project discussions and technical inquiries.

Reference

Cai, Yu et al. "Artificial intelligence applied in neoantigen identification facilitates personalized cancer immunotherapy." Frontiers in oncology vol. 12 1054231. 9 Jan. 2023. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fonc.2022.1054231

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.